孙金堂;魏见伟;隋光善;关振鹏;

• 1:山东省即墨市人民医院骨外科
• 2:北京大学人民医院骨关节科

摘要(Abstract)：

(osteoporosis,OP)是一种多病因的全身性骨骼疾病,它是指以骨量降低、骨组织微细结构退变导致骨强度下降、骨脆性增加及骨折危险性增大为特征的代谢性疾病。随着人类寿命的延长和社会老龄化的发展,骨质疏松所导致的骨折在大大增加老年人病残率和病死率的同时,明显加重了社会公共卫生的经济负担,成为更加严重的世界性公共健康问题。狄诺塞麦(Denosumab)是目前用于治疗绝经期骨质疏松的第一种单克隆抗体药物。它能与细胞核因子-κB受体活化因子配体(RANKL)结合,通过抑制破骨细胞的产生、功能和存活,减少骨吸收达到治疗作用。狄诺塞麦有希望成为治疗骨质疏松的新选择。本文就狄诺塞麦的药理学特性、生物学作用机制及临床相关研究等方面进行综述。

关键词(KeyWords)： 狄诺塞麦;骨质疏松;绝经;治疗

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 孙金堂;魏见伟;隋光善;关振鹏;

Email:

DOI:

参考文献(References)：

• [1]Management of osteoporosis in postmenopausal women:2010 position statement of the North American Menopause Society[J].Menopause,2010,17(1):25-54.
• [2]Watts NB,Bilezikian JP,Camacho PM,et al.American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis[J].Endocr Pract,2010,16(3):1-37.
• [3]Laura M,Toni I,Emanuele S,et al.Bone metastases detection by circulating biomarkers:OPG and RANK-L[J].Int J Oncol,2011,39(1):255-261.
• [4]Boyle WJ,Simonet WS,Lacey DL.Osteoclast differentiation and activation[J].Nature,2003(6937),423:337-342.
• [5]Boyce BF,Hughes DE,Wright KR,et al.Recent advances in bone biology provide insight into the pathogenesis of bone diseases[J].Lab Invest,1999,79(2):83-94.
• [6]Lewiecki EM.Treatment of osteoporosis with denosumab[J].Maturitas,2010,66(2):182-186.
• [7]Chitre M,Shechter D,Grauer A.Denosumab for treatment of postmenopausal osteoporosis[J].Am J Health Syst Pharm,2011,68(15):1409-1418.
• [8]Moen MD,Keam SJ.Denosumab:a review of its use in the treatment of postmenopausal osteoporosis[J].Drugs Aging,2011,28(1):63-82.
• [9]Reginster JY.Antifracture efficacy of currently available therapies for postmenopausal osteoporosis[J].Drugs,2011,71(1):65-78.
• [10]Santini D,Galluzzo S,Zoccoli A,et al.New molecular targets in bone metastases[J].Cancer Treat Rev,2010,36(3):S6-S10.
• [11]European MA.Prolia 60 mg solution in a prefilled syringe:summary of product characteristics[EB/OL].2013.http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001120/WC500093526.pdf.Accessed 26 Nov 2013.
• [12]Amgen Manufacturing Limited.Prolia_(denosumab)injection,for subcutaneous use:US prescribing information[EB/OL].2013.http://pi.amgen.com/united_states/prolia/prolia_pi.pdf.Accessed26 Nov 2013.
• [13]Akiyama T,Shinzawa M,Akiyama N.RANKL-RANK interaction in immune regulatory systems[J].World J Orthop,2012,3(9):142-150.
• [14]Michael MR,Michael LE,Stanley CB,et al.Denosumab in postmenopausal women with low bone mineral density[J].N Engl J Med,2006,354(8):821-831.
• [15]Henry BG,Michael BA,Yuen CK,et al.Effects of denosumab on bone mineral density and bone turnover in postmenopausal women[J].J Clin Endocrinol Metab,2008,93(6):2149-2157.
• [16]Kendler DL,Roux C,Benhamou CL,et al.Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy[J].J Bone Miner Res,2010,25(1):72-81.
• [17]Brown JP,Prince RL,Deal C,et al.Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass:a randomized,blinded,phase 3 trial[J].J Bone Miner Res,2009,24(1):153-161.
• [18]RenéR,Jean-Yves R,Steren B,et al.Adverse reactions and drugdrug interactions in the management of women with postmenopausal osteoporosis[J].Calcif Tissue Int,2011,89(2):91-104.
• [19]Lin T,Wang C,Cai XZ,et al.Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis:a meta-analysis[J].Int J Clin Pract,2012,66(4):399-408.
• [20]Bekker PJ,Holloway DL,Rasmussen AS,et al.A single-dose placebo-controlled study of AMG 162,a fully human monoclonal antibody to RANKL,in postmenopausal women[J].J Bone Miner Res,2004,19(7):1059-1066.
• [21]Cummings SR,San Martin J,Mc Clung MR,et al.Denosumab for prevention of fractures in postmenopausal women with osteoporosis[J].N Engl J Med,2009,361(8):756-765.
• [22]Bergan J.Prolia product information[EB/OL].FDA,2010[201-1-5].http://www.accessdata.Fda.gov/drugsatfda_docs/label/2010/125320s0000lbl.Pdf.
• [23]George S.Review of Prolia[EB/OL].FDA,2010[201-1-5].http://www.accessdata.fda.gov/dru gsatfda_docs/nda/2010/125320s000SumR.Pdf.
• [24]Lipton A,Siella S,Rader M,et al.Compgrison of denosumab versus zoledronic add(Z)for treatment of bone metastases in advanced cancer patiems:an imegrated analysis of 3 pivotal trials[J].Eur Soc Med Oncol(EBMO),2010,49(2):416-430.